CRISPR Therapeutics (CRSP) In Q1 of 2024, the company reported a net loss of $116.6 million, a significant increase from the prior year's $53 million. This was due to CRSP's strategic investments in R&D and market expansion for Casgevy. Despite this, the firm boasts a robust cash reserve of approximately $2.1 billion, underpinning its capacity for sustained growth and further drug approvals expected in the next two to three years. Vertex Pharmaceuticals (NASDAQ:VRTX) is known for its pioneering cystic fibro ...